Sign in
Taking people in United StatesNo phase

Pharmacist-led care to lower uric acid in people with gout

Compares two ways of managing uric acid-lowering medicines in adults with gout.

Key facts

Who runs it
VA Office of Research and Development
Where
Omaha, Philadelphia, Portland, Salt Lake City, and Seattle, United StatesSee the 5 sites
Trial code
Registry title
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
Status
Recruiting
People taking part
310 people, planned
Started
1 Oct 2026
Expected to end
30 Mar 2031
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Pharmacist-Led
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for US Veterans with gout and high uric acid who had flares recently. It compares pharmacist-led care with usual care for uric acid-lowering medicine.

Age
18 Years and older
Sex
All sexes can join.
Disease stage
Gout diagnosed by a doctor that meets the ACR/EULAR gout classification criteria. People must report 1 or more flares in the prior 6 months.
Earlier treatment
People must have a new prescription for urate-lowering therapy (allopurinol or febuxostat) from a primary care provider. People on longer-term urate-lowering therapy can also join if they meet the flare and uric acid criteria.
Biomarker or test result
High blood uric acid level (SU > 6.8 milligrams per deciliter).

Main reasons for not taking part

  • Cannot take or does not tolerate allopurinol or febuxostat
  • A visit with a rheumatologist (joint specialist) in the prior 3 months
  • Allopurinol dose > 300 or Febuxostat dose > 40
  • Stage IV/V chronic kidney disease, or life expectancy < 12 months
  • Taking azathioprine or 6-MPC

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • US Veterans with physician-diagnosed
  • Documented hyperuricemia (SU > 6.8 milligrams per deciliter)
  • Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria
  • Report 1 or more flares in the prior 6 months
  • Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria

Who cannot take part

  • Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat)
  • Patients with a rheumatology encounter within the prior 3 months
  • Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated)
  • Patients with stage IV/V Chronic Kidney Disease (CKD)
  • Patients on an allopurinol dose > 300 or a Febuxostat dose > 40
  • Patients with a life expectancy < 12 months

Where in United States

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesContact: Bridget KramerTaking people
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, United StatesContact: Criswell Lavery, MPHTaking people
  • VA Portland Health Care System, Portland, ORPortland, United StatesContact: Alexandra BennettTaking people
  • VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesContact: Jennifer GodinaTaking people
  • VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Hannah BrubeckTaking people

About the trial

What the trial wants to find out

This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.

The 2 groups in the trial

  • Pharmacist-LedTreatment being tested

    Veterans will participate in regular telehealth visits with study pharmacists. Serum urate lab tests will be ordered during dose escalation phase of gout treatment.

  • Usual careNo study treatment, for comparison

    Veterans will receive standard care from their primary care provider for the management of their gout.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
Plain-language title
Pharmacist-led care to lower uric acid in people with goutGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
21 October 2026